5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation.

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 1 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 3 , 8 , 31 , 15 , 32 , Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation and Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
      The Journal of Infectious Diseases
      Oxford University Press
      Seasonal human coronavirus, HCoV-NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1, community-acquired respiratory virus, allogeneic hematopoietic stem cell transplantation, immunocompromised, upper and lower respiratory tract disease, immunodeficiency score index, multiplex PCR assay

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Little is known about characteristics of seasonal human coronavirus (HCoV) (NL63, 229E, OC43 and HKU1) after allogeneic stem cell transplantation (allo-HCT).

          Patients and methods

          this is a collaborative Spanish and European bone marrow transplantation groups retrospective multicentre study, which included allo-HCT recipients (adults and children) with upper and/or lower respiratory tract disease (U/LRTD) caused by seasonal HCoV diagnosed through multiplex PCR assays from January 2012 to January 2019.

          Results

          We included 402 allo-HCT recipients who developed 449 HCoV U/LRTD episodes. Median age of recipients was 46 years (range 0.3-73.8 years). HCoV episodes were diagnosed at a median of 222 days after transplantation. The most common HCoV subtype was OC43 (n=170, 38%). LRTD involvement occurred in 121 episodes (27%). HCoV infection frequently required hospitalization (18%), oxygen administration (13%) and intensive care unit (ICU) admission (3%). Three-month overall mortality after HCoV detection was 7% in the whole cohort and 16% in those with LRTD. We identified 3 conditions associated with higher mortality in recipients with LRTD: absolute lymphocyte count <0.1 x10 9/mL [hazard ratio (HR), 10.8], corticosteroid (HR 4.68) and ICU admission (HR 8.22) (p<0.01).

          Conclusions

          Seasonal HCoV after allo-HCT may involve the LRTD in many instances, leading to a significant morbidity.

          Related collections

          Author and article information

          Journal
          J Infect Dis
          J. Infect. Dis
          jid
          The Journal of Infectious Diseases
          Oxford University Press (US )
          0022-1899
          1537-6613
          29 August 2020
          : jiaa553
          Affiliations
          [1 ] Hematology división, Hospital universitario y politécnico La Fe, Valencia, Spain, CIBERONC, Instituto Carlos III , Madrid, Spain
          [2 ] Service d’Hématologie-Greffe, Hôpital Saint-Louis, Université Paris-Diderot , Paris, France
          [3 ] Azienda Ospedaliera Universitaria Integrata Verona , Verona, Italy
          [4 ] University Hospital Basel , Basel, Switzerland
          [5 ] EBMT Data Office Leiden , Leiden, The Netherlands
          [6 ] Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia ASST Spedali Civili di Brescia , Brescia, Italy
          [7 ] Hematology división, Hospital Morales Meseguer , Murcia, Spain
          [8 ] Hematology división, Hospital Clínico de Valencia , Valencia, Spain
          [10 ] Willem Alexander Children’s Hospital/Leiden University Medical Center , Leiden, The Netherlands
          [11 ] Hematology división, Hospital Universitario de Salamanca , Salamanca, Spain
          [12 ] Hematology división, Hospital Clínic, Barcelona , Spain
          [13 ] Turku University Hospital , Turku, Finland
          [14 ] Demiroglu Bilim University , Istanbul, Turkey
          [15 ] Hematology división, Hospital de la Princesa , Madrid, Spain
          [16 ] Erciyes University, Faculty of Medicine, Erciyes Pediatric BMT Center , Kayseri, Turkey
          [17 ] King Abdulaziz Medical City , Riyadh, Saudi Arabia
          [18 ] University Medical Center Groningen, University of Groningen , Groningen, The Netherlands
          [19 ] Hematology división, Hospital Regional de Málaga , Malaga, Spain
          [20 ] Hematology división, ICO-Hospital Germans Trias i Pujol, Barcelona , Spain
          [21 ] Universita Cattolica S. Cuore , Rome, Italy
          [22 ] Radboud University Medical Center , Nijmegen, The Netherlands
          [23 ] Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation. Hannover Medical School , Hannover, Germany
          [24 ] Hacettepe University Children’s Hospital , Ankara, Turkey
          [25 ] Centre Hospitalier Lyon Sud, Hospices Civils de Lyon , Lyon, France
          [26 ] The Children’s Hospital at Westmead , Sydney, Australia
          [27 ] Gazi University Faculty of Medicine , Ankara, Turkey
          [28 ] Pediatric división, Niño Jesus Children’s Hospital , Madrid, Spain
          [29 ] Hospital Sirio-Libanes , São Paulo, Brazil
          [30 ] Children's University Hospital Queen Fabiola, Université Libre de Bruxelles , Brussels, Belgium
          [31 ] University of Genoa (DISSAL) and IRCCS Ospedale Policlinico San Martino , Genova, Italy
          [32 ] Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun UMK, University Hospital , Bydgoszcz, Poland
          Author notes
          Correspondence: MD. Jose Luis Piñana, Division of Clinical Hematology, Hospital Universitario la Fe de Valencia, Avda Fernando Abril Martorell, 106 CP 46026 Valencia, Spain, Phone: +34 96 1244628 Fax: +34 96 1246201, E-mail: jlpinana@ 123456gmail.com
          Article
          jiaa553
          10.1093/infdis/jiaa553
          7499673
          32860509
          b156f6df-8308-4ba9-93c3-a0883cf75235
          © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

          This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

          This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

          History
          : 30 June 2020
          Categories
          Major Article
          AcademicSubjects/MED00290
          Custom metadata
          PAP
          accepted-manuscript

          Infectious disease & Microbiology
          seasonal human coronavirus,hcov-nl63,hcov-229e,hcov-oc43,hcov-hku1,community-acquired respiratory virus,allogeneic hematopoietic stem cell transplantation,immunocompromised,upper and lower respiratory tract disease,immunodeficiency score index,multiplex pcr assay

          Comments

          Comment on this article